hat
J147 dwòg alzayme a te premye devlope nan 2011, ak chèchè yo te pote soti etid plizyè ki montre li ka ranvèse pèt memwa ak ralanti oswa ranvèse alzayme a nan sourit yo. Men, jouk etid sa a, yo pa t 'konnen ki jan dòz J147 travay nan selil yo. Yo te kapab montre ke J147 travay pa manipile ATP, yon pwoteyin nan mitokondri a ak sous mobil kò a nan enèji. Lè J147 te prezan, newòn yo te pwoteje kont toksisite ki asosye ak aje. Eksperyans adisyonèl te montre ke J147 ogmante nivo yo nan ATP ak fè pwomosyon an sante, pi stab mitokondri.
eng
Alzheimer’s drug J147 was first developed in 2011, and researchers have carried out several studies that show it can reverse memory loss and slow or reverse Alzheimer’s in mice. But until this study, they didn’t know how dose J147 work within cells. They were able to show that J147 works by manipulating ATP, a protein in the mitochondria and the body’s mobile source of energy. When J147 was present, neurons were protected from toxicities associated with aging. Additional experiments showed that J147 increases the levels of ATP and promotes healthier, more stable mitochondria.